NanoSphere Health Sciences Inc (NSHS) AI Stock Analysis

• Market Cap: C$359.63K
• Dividend Yield: N/A
• Average Volume (3M): 3.44K
• Price to Earnings (P/E): 1.2
• Beta (1Y): -3.55
• Revenue Growth: N/A
• EPS Growth: 24.57%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 10,275,205
• 10 Day Avg. Volume: 1,250
• 30 Day Avg. Volume: 3,435
• PEG Ratio: 0.05
• Price to Book (P/B): -5.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.38
• Enterprise Value/Market Cap: 14.11
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -8.52
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 30 Underperform
• Price Target: ―

NanoSphere Health Sciences Inc. has major financial challenges, with no revenue and high liabilities significantly impacting its score. While technical indicators display some positive momentum, the severe financial issues and poor valuation metrics weigh heavily on the overall assessment.

NanoSphere Health Sciences Inc Business Overview & Revenue Model

Company Description

NanoSphere Health Sciences Inc (NSHS) is a biotechnology company focused on the development and commercialization of advanced delivery systems for nutraceuticals and pharmaceuticals. The company leverages its patented NanoSphere Delivery System to enhance the bioavailability and efficacy of therapeutic agents, including cannabinoids, vitamins, and other nutrients. NanoSphere Health Sciences operates in the health sciences sector, providing innovative solutions that improve the delivery and absorption of compounds in the human body.

How the Company Makes Money

NanoSphere Health Sciences Inc makes money primarily through the commercialization and licensing of its NanoSphere Delivery System technology. The company generates revenue by partnering with nutraceutical and pharmaceutical companies to integrate its delivery system into their products, thereby enhancing their value proposition. Additionally, NanoSphere Health Sciences may earn revenue from direct sales of products developed using its technology, as well as through strategic partnerships and collaborations that provide access to new markets and revenue streams. Key factors contributing to its earnings include the effectiveness of its technology, the ability to secure partnerships with industry leaders, and the expansion of its product portfolio.

NanoSphere Health Sciences Inc Financial Statement Overview

Summary

NanoSphere Health Sciences Inc. exhibits severe financial distress, with no revenue generation, high liabilities, negative equity, and cash flow issues. These factors indicate a critical need for strategic restructuring or additional funding to stabilize operations.

Income Statement

The company reported zero revenue over the analyzed periods, indicating an absence of sales. This is a significant weakness, as it implies a lack of commercial activity. Additionally, consistent negative EBIT and net income highlight persistent operating losses, which are unsustainable long-term.

Balance Sheet

The company has negative stockholders' equity, indicating liabilities exceed assets, raising concerns about financial stability. The consistently high total liabilities compared to assets suggest potential solvency issues without significant corrective actions.

Cash Flow

Operating cash flows are negative, reflecting ongoing cash outflows from operations. There is no capital investment, and the free cash flow is consistently negative, questioning the company's ability to sustain operations without external financing.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	218.03K
	Gross Profit
0.00	0.00	0.00	0.00	0.00	218.03K
	EBIT
-74.80K	-220.00K	-263.00K	-355.00K	-529.77K	-3.24M
	EBITDA
-187.77K	0.00	-286.00K	-341.00K	-529.77K	-3.32M
	Net Income Common Stockholders
-144.08K	-228.00	-282.00K	-356.00K	-591.22K	-3.47M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
11.81K	9.32K	55.01K	130.76K	12.95K	33.46K
	Total Assets
22.89K	17.97K	60.05K	132.51K	55.19K	333.72K
	Total Debt
31.96K	0.00	0.00	0.00	73.73K	149.46K
	Net Debt
20.14K	-9.32K	-55.01K	-130.76K	60.78K	116.00K
	Total Liabilities
1.71M	1.57M	1.37M	1.21M	1.51M	1.25M
	Stockholders Equity
-1.68M	-1.56M	-1.31M	-1.08M	-1.45M	-919.49K
Cash Flow		Free Cash Flow
-30.98K	-53.70K	-67.66K	-64.68K	-47.26K	-1.13M
	Operating Cash Flow
-30.98K	-53.70K	-67.66K	-64.68K	-47.26K	-1.08M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	-382.38K
	Financing Cash Flow
0.00	0.00	0.00	182.43K	34.27K	1.28M

NanoSphere Health Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NSHS, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 19.58 is Positive, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NSHS.

NanoSphere Health Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OGI	73 Outperform	$262.41M	19.21	4.76%	―	26.93%	―
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
ACB	50 Neutral	C$452.79M	35.61	4.78%	―	16.39%	-98.10%
NSHS	30 Underperform	C$359.63K	1.24	8.55%	―	―	24.57%